alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.20





 Exhibit 10.20 

SECOND AMENDMENT 
 TO
LEASE AGREEMENT 
  

					
	STATE OF TEXAS	  	X	  	
		  	X	  	KNOW ALL PERSONS BY THESE PRESENTS:
	COUNTY OF TRAVIS	  	X	  	

 That this Amendment to the Lease Agreement is made as of the 26th day of June, 2019, between 601 Congress
LP, Landlord, and Hippo Analytics Inc., Tenant; 
 WITNESSETH 

WHEREAS, the Landlord and Tenant have executed that certain Lease Agreement on or about January 30, 2019, covering approximately 3,814 rentable
square feet (known as Suite 200) of office space on the second floor of the Littlefield Building in Austin, Texas, located at 601 Congress Avenue; and 

WHEREAS, the Landlord and Tenant have executed that certain Lease Amendment on or about May 9, 2019, covering approximately 2,012 rentable square
feet (known as Suite 330) of office space on the third floor of the Littlefield Building in Austin, Texas, located at 601 Congress Avenue; 
 WHEREAS, the
Landlord and Tenant desire to amend the Lease Agreement to provide for an expansion of the Premises and an extension of all existing lease spaces; 
 NOW
THEREFORE, for and in consideration of the mutual promises and covenants set forth herein, the Landlord and Tenant agree that the Lease is amended as follows effective June 26th, 2019: 

1. Expansion of Premises – The Premises is being expanded to include Suite 750 being 4,496 rentable square feet 

2. Base Rent – “Base Rent” for Suite 750 is as shown below: 

$14,986.67 per month for the period of August 1, 2019 to January 31, 2020 

$15,436.27 per month for the period of February 1, 2020 to January 31, 2021 

$15,899.35 per month for the period of February 1, 2021 to January 31, 2022 

$16,376.34 per month for the period of February 1, 2022 to July 31, 2022 

3. Base Rent – The extended “Base Rent” for Suites 200 is as shown below: 

$13,487.57 per month for the period of February 1, 2021 to January 31, 2022 

$13,892.20 per month for the period of February 1, 2022 to July 31, 2022 

4. Base Rent – The extended “Base Rent” for Suites 330 is as shown below: 

$7,115.11 per month for the period of February 1, 2021 to January 31, 2022 

$7,328.56 per month for the period of February 1, 2022 to July 31, 2022 

5. NNN Charges – Section 9 of the Lease shall be apply to the Suite 750 upon August 1, 2019. Tenant’s Common Area
Maintenance, Property Taxes and Casualty Insurance contribution following August 1, 2019 shall be adjusted to 10.23%. 
 6. Condition
of Premises – Prior to the August 1, 2019, Landlord shall replace the damaged carpet, repair the damaged wood floors, and repaint the Premises for Suite 750. 

7. Landlord and Tenant ratify and affirm all terms and provisions of the Lease Agreement except as modified by the terms of this Amendment.














									
	EXECUTED this 26th day of June, 2019.	 		 	
			
	LANDLORD:	 		 	TENANT:
	601 Congress, LP	 		 	Hippo Analytics Inc.
					
	By:	 	 /s/ Sheldon David Kahn
	 		 	By:	 	 /s/ Rick McCathron

	By:	 	Sheldon David Kahn	 		 	Name:	 	Rick McCathron
	Title:	 	Manager	 		 	Title:	 	Chief Insurance Officer
	Date:	 	6/27/2019	 		 	Date:	 	6/25/2019
(56 Misc. Rep. 66.)

#### WOOD v. HOFFMAN et al.*

(Supreme Court, Special Term, New York County.

September, 1907.)

Discovery—Physical Examination.

An order providing, under Code-Civ. Proc. §§ 870, 872, 873, for the examination of plaintiff before a referee, and for a physical examination-by a physician and a subsequent examination of the physician before a referee, is unwarranted as to the latter provision.

Action by Bertram Wood against Charles W. Hoffman and ErnestFlagg. Motion to vacate order for examination of plaintiff. Modified.

Feltenstein & Rosenstein, for plaintiff.

Beaty & Burlingame, for defendants.

*

For opinion of Appellate Division, see 106 N. Y. Supp. 308.

BRADY, J.

This is a motion to vacate and set aside an order made-for the examination of the plaintiff as an adverse party under sections 870, 873 and 873 of the Code of Civil Procedure. The order directs-the plaintiff to appear for examination before a referee, and also directs a physical examination by a physician, and further directs the-examination of the physician before the referee as to the result of his examination. In so far as the order directs or permits the examination of the physician it is clearly unwarranted. I can find no provision of law which permits it. The section of the Code of Civil Procedure (873) contemplates a physical examination of the party by the physician which includes such oral examination as the physician thinks-proper, and of the questions and answers the referee can make a record; but.the physician cannot be examined himself as to the result until the trial. This conclusion I believe to be amply supported by the opinions of the court in Lyon v. Manhattan R. Co., 143 N. Y. 398, 37 N. E. 113, 35 L. R. A. 403; Matter of Davies, 168 N. Y. 108, 61 N. E. 118, 56 L. R. A. 855; Potter v. Village of Hammondport, 113 App. Div. 91, 98 N. Y. Supp. 186.

The order is modified, so as to strike out the provision for the examination of the physician. Settle order on notice.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                           3,986
<SECURITIES>                                         0
<RECEIVABLES>                                  588,693
<ALLOWANCES>                                         0
<INVENTORY>                                    109,405
<CURRENT-ASSETS>                               781,436
<PP&E>                                         630,336
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               1,448,987
<CURRENT-LIABILITIES>                          847,135
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        36,513
<OTHER-SE>                                    (34,900)
<TOTAL-LIABILITY-AND-EQUITY>                 1,448,987
<SALES>                                      3,341,480
<TOTAL-REVENUES>                             3,341,480
<CGS>                                        2,056,752
<TOTAL-COSTS>                                3,210,730
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              92,838
<INCOME-PRETAX>                              (137,340)
<INCOME-TAX>                                     1,600
<INCOME-CONTINUING>                          (138,940)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                 30,487
<CHANGES>                                            0
<NET-INCOME>                                 (108,453)
<EPS-BASIC>                                     (.004)
<EPS-DILUTED>                                   (.004)


</TABLE>
a102amendment2tothecomme






Document No:  Revision:  Revision Date:  Replaces:  Page:  MSA-XPI  Amendment 2  05/13/21  00  1 of 4          AMENDMENT NO. 2 TO Commercial Supply Agreement    This Amendment No. 2 to the Commercial Supply Agreement (this “Amendment”) has  been made and entered into as of May 13, 2021 (the “Effective Date”) between PYRAMID  Laboratories Inc. (“PYRAMID”) and Xeris Pharmaceuticals, Inc. (“Client”). This Amendment  amends that certain Commercial Supply Agreement dated as of May 14, 2018 (the “Agreement”)  and amended on September 1, 2018 (“Amendment 1”), by and between the parties to this  Amendment. Capitalized terms used but not otherwise defined herein shall have the meanings  ascribed to them in the Agreement.    NOW, THEREFORE, the parties intending to be legally bound, hereby agree as follows:    1. Schedule A. The Agreement is hereby amended as of the Effective Date such that Schedule  A thereto is deleted in its entirety and replaced with Schedule A attached hereto.    2. Miscellaneous. Except as expressly amended hereby, the terms of the Agreement  (including the schedules thereto) shall remain in full force and effect, and the Agreement,  as amended by this Amendment, is binding on each of the parties to this Amendment.    * * *  





 






Document No:  Revision:  Revision Date:  Replaces:  Page:  MSA-XPI  Amendment 2  05/13/21  00  2 of 4          IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the  Effective Date.        PYRAMID Laboratories, Inc.:          By: /s/ Medhat Gorgy   Name: Medhat Gorgy  Title: President & CEO  Xeris Pharmaceuticals, Inc.:      By: /s/ Kevin McCulloch   Name:            Kevin McCulloch  Title:              SVP, Global Operations 





 






Document No:  Revision:  Revision Date:  Replaces:  Page:  MSA-XPI  Amendment 2  05/13/21  00  3 of 4      Schedule A      Batch Size, Dosage, Yield*, Volume, Pricing        [***]    [***]   [***]   [***]    [***]   [***]   [***]  [***]   [***]   [***]  [***]   [***]   [***]    [***]    [***]   [***]   [***]    [***]   [***]   [***]  [***]   [***]   [***]  [***]   [***]   [***]    [***]    [***]   [***]   [***]    [***]   [***]   [***]  [***]   [***]   [***]  [***]   [***]   [***]    [***]    [***]   [***]   [***]    [***]   [***]   [***]  [***]   [***]   [***]  [***]   [***]   [***]  





 






Document No:  Revision:  Revision Date:  Replaces:  Page:  MSA-XPI  Amendment 2  05/13/21  00  4 of 4        Schedule A (continued)    Batch Size, Dosage, Yield, Volume Pricing    Pricing Assumptions:    1. Standard Batch [***].    2. Standard batch size estimates based on [***] theoretical yield per dosage; yield assumptions and  batch sizes shall be adjusted annually based on actual production history.    3. Batch size/yield/price independent [***].    4. Pricing subject to annual adjustments as defined under Section 3.3.2 [***].    5. Pricing for Validation Batches shall be adjusted as defined under Section 3.3.3 [***].    6. Price includes [***].    7. Price includes [***].    8. Price excludes [***].
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING

MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL

OF FLORIDA

SECOND DISTRICT

ARTEZ HOOKER, )

)

Appellant, )

)

v. ) Case No. 2D18-3884

)

STATE OF FLORIDA, )

)

Appellee. )

___________________________________)

Opinion filed July 17, 2019.

Appeal pursuant to Fla. R. App. P. 

9.141(b)(2) from the Circuit Court for 

Pinellas County; Frank Quesaeda, Judge. 

J. Andrew Crawford of J. Andrew Crawford, 

P.A., Saint Petersburg, for Appellant. 

PER CURIAM.

Affirmed.

NORTHCUTT, LaROSE, and SALARIO, JJ., Concur.
UNITED STATES DISTRICT COURT

FOR THE Northern District of Illinois − CM/ECF LIVE, Ver 2.3

Eastern Division

Katherine Albrecht, et al.

Plaintiff,

v. Case No.:

1:03−cv−06472

Hon. Morton

Denlow

Metropolitan Pier and Exposition Authority, et al.

Defendant.

NOTIFICATION OF DOCKET ENTRY

This docket entry was made by the Clerk on Thursday, April 14, 2005:

 MINUTE entry before Judge Morton Denlow :Magistrate Judge Status hearing

held on 4/14/2005. Status hearing set for 5/19/2005 at 10:00 AM.Judicial staff mailed

notice(dmk, )

ATTENTION: This notice is being sent pursuant to Rule 77(d) of the Federal Rules of

Civil Procedure or Rule 49(c) of the Federal Rules of Criminal Procedure. It was

generated by CM/ECF, the automated docketing system used to maintain the civil and

criminal dockets of this District. If a minute order or other document is enclosed, please

refer to it for additional information.

For scheduled events, motion practices, recent opinions and other information, visit our

web site at www.ilnd.uscourts.gov.

Case: 1:03-cv-06472 Document #: 65 Filed: 04/14/05 Page 1 of 1 PageID #:401
EXHIBIT 99.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In  connection  with  the annual report of eLinear, Inc. (the "Company") on Form
10-KSB  for  the  year  ended December 31, 2002 as filed with the Securities and
Exchange  Commission  on the date hereof (the "Report"), I, Jon V. Ludwig, Chief
Executive  Officer and Chief Financial Officer of the Company, certify, pursuant
to  18  U.S.C.  section  1350,  as  adopted  pursuant  to  Section  906  of  the
Sarbanes-Oxley  Act  of  2002,  that  to  the  best  of  my  knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2)  The  information  contained  in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.



/s/ Jon V. Ludwig
------------------------------
Jon V. Ludwig, Chief Executive Officer and
Chief Financial Officer
April 15, 2003


     A  signed  original  of  this written statement required by Section 906 has
been  provided  to  eLinear,  Inc.  and  will  be  retained by eLinear, Inc. and
furnished  to  the Securities and Exchange Commission or its staff upon request.


<PAGE>
**Exhibit 32.1**

 

**Certification of the Chief Executive OfficerPursuant to18 U.S.C. Section 1350,as Adopted Pursuant toSection 906 of the Sarbanes-Oxley Act of 2002**

 

In connection with the Quarterly Report on Form 10-Q of PRAECISPHARMACEUTICALS INCORPORATED (the “Company”) for the quarterly period endedJune 30, 2004 as filed with the Securities and Exchange Commission on thedate hereof (the “Report”), I, Malcolm L. Gefter, Ph.D., as Chief ExecutiveOfficer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, asadopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to thebest of my knowledge:

 

1.  The Report fully complieswith the requirements of Section 13(a) or 15(d) of the Securities ExchangeAct of 1934; and

 

2.  The information contained inthe Report fairly presents, in all material respects, the financial conditionand results of operations of the Company.

 

 
| /s/ Malcolm L. Gefter, Ph.D. |                     |
|------------------------------|--------------------------|
| Name:                        | Malcolm L. Gefter, Ph.D. |
| Title:                       | Chief Executive Officer  |
| Date:                        | August 9, 2004      |
|                              |                          |  |

 

 

A signed original of this written statement required bySection 906, or other document authenticating, acknowledging, or otherwiseadopting the signature that appears in typed form within the electronic versionof this written statement required by Section 906, has been provided toPRAECIS PHARMACEUTICALS INCORPORATED and will be retained by PRAECISPHARMACEUTICALS INCORPORATED and furnished to the Securities and Exchange  Commissionor its staff upon request.

 

This certification accompanies the Report pursuant to Section 906of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent requiredby the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposesof Section 18 of the Securities Exchange Act of 1934, as amended.

 

----
EXHIBIT 99.1

Certification  of  Chief  Executive  Officer  Pursuant  to  Section  906  of the
Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

In connection with the Quarterly Report of Ingenuus  Corporation (the "Company")
on Form 10-Q for the period ended  August 31, 2002 as filed with the  Securities
and  Exchange  Commission  on the date  hereof  (the  "Report"),  I,  Michael J.
Carroll, Chief Executive Officer of the Company,  certify, pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.

/s/ Michael J. Carroll
----------------------
Michael J. Carroll
Chairman and Chief Executive Officer

October 15, 2002

<PAGE>


Certification  of  Chief  Financial  Officer  Pursuant  to  Section  906  of the
Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

In connection with the Quarterly Report of Ingenuus  Corporation (the "Company")
on Form 10-Q for the period ended  August 31, 2002 as filed with the  Securities
and Exchange Commission on the date hereof (the "Report"), I, Randy Singh, Chief
Financial Officer of the Company,  certify,  pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.

/s/ Randy Singh
----------------------
Randy Singh
Chief Financial Officer

October 15, 2002
**Exhibit 23.1**

 

**Consent of Independent Auditors**

 

We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-109755, 333-103595, 333-80065, 333-06563,333-11451, 333-35651, 333-28929, 333-28927, 333-71913, and 333-80963) of our report dated January 16, 2004, with respect to the consolidated financial statements and schedule of Secure Computing Corporation included in the Annual Report (Form 10-K)for the year ended December 31, 2003.****

 

/s/ Ernst & Young LLP 

 

Minneapolis, Minnesota 

March 9, 2004 

 

48
EXHIBIT
32.1





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES OXLEY ACT OF 2002


CERTIFICATION





In
connection with the Annual Report of Power Sports Factory, Inc. (the "Company")
on Form 10-K for the year ended December 31, 2009 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"),  I, Shawn
Landgraf, Chief Executive Officer of
the  Company,  certify,  pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of
the  Sarbanes-Oxley Act of 2002, that to the best of my
knowledge:





(1) The
Report fully complies with the  requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and





(2)
The  information  contained in the
Report  fairly  presents,  in all
material  respects,  the  financial  condition and
result of  operations of the Company.





/s/Shawn
Landgraf


Shawn
Landgraf


Chief
Executive Officer


April 15,
2010
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER>  1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                          58,391
<SECURITIES>                                         0
<RECEIVABLES>                                   30,545
<ALLOWANCES>                                     1,144
<INVENTORY>                                          0
<CURRENT-ASSETS>                                90,430
<PP&E>                                          13,198
<DEPRECIATION>                                   5,059
<TOTAL-ASSETS>                                 111,801
<CURRENT-LIABILITIES>                           25,391
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           249
<OTHER-SE>                                      85,133
<TOTAL-LIABILITY-AND-EQUITY>                   111,801
<SALES>                                         44,198
<TOTAL-REVENUES>                                44,198
<CGS>                                           19,562
<TOTAL-COSTS>                                   39,210
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                (270)
<INCOME-PRETAX>                                  5,258
<INCOME-TAX>                                     2,066
<INCOME-CONTINUING>                              3,192
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,192
<EPS-PRIMARY>                                      .14
<EPS-DILUTED>                                      .13
        

</TABLE>
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Soil Management and Sugarbeet Research: Fort Collins, CO
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                                    Software
                People

                    Staff Listing
                                    CareersSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Plains Area Fort Collins, Colorado Center for Agricultural Resources Research Soil Management and Sugarbeet Research People & Locations







Robert  D`Adamo
                        Soil Management and Sugarbeet Research

                        




                        
                        Physical Science Technician
                        Phone: (970) 492-7224
                        
                        
                        Fax: (970) 492-7213(Employee information on this page comes from the REE Directory. Please contact your front office staff to update the REE Directory.)


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov